Adjuvant systemic treatment for individual patients with triple negative breast cancer

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Oakman, Catherine ^a   Moretti, Erica ^a   Galardi, Francesca ^a   Biagioni, Chiara ^a   Santarpia, Libero ^a   Biganzoli, Laura ^a   Di Leo, Angelo ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Adjuvant chemotherapy; Anthracycline; Platinum; Triple negative breast cancer

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOUBLE STRANDED DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HISTONE H2AX; METHOTREXATE; NAVELBINE; PACLITAXEL; PROTEIN P63; PROTEIN P73; RAD51 PROTEIN; UBIQUITIN;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CHEMOSENSITIVITY; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

EID: 80054858200     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70311-3     Document Type: Article

References (76)

1. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
2. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
3. Huober JB, Gelber S, Thiirlimann B, et al. Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. J Clin Oncol 2010, 28:15s. (abstract 630).
4. Weigelt B, Baehner FL, Reis-Filho JS, et al. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
5. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers?. IntJ Cancer 2008, 123:236-240.
6. Kandel M, Stadler Z, Masciari S, et al. Prevalence of BRCA-1 mutations in triple negative breast cancer (BC)J. Clin Oncol 2006, 24:18s. (abstract 508).
7. Turner N, Tutt A, Ashworth A Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
8. Le Tourneau C, Dettwiler S, Laurence V, et al. 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat 2007, 106:1s. (abstract 4010).
9. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage 11/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007, 7:203.
10. Bidard FC, Matthieu MC, Chollet R, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008, 19:1261-1265.
11. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
12. Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Can To Kagaku Ryoho 2009, 36:255-258.
13. Fernandez-Morales L, Dalmau E, Martinez S, et al. Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status. J Clin Oncol 2006, 24:18s. (abstract 626).
14. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010, 124:133-140.
15. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
16. Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J Clin Oncol 2009, 27:18s. (abstract LBA515).
17. Parker JS, Prat A, Cheang MCU, et al. Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy. Cancer Res 2009, 69:24s. (abstract 2019).
18. Rouzier R, Perou C, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
19. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
20. Gennari A, Sormani MP, Pronzato R, et al. HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J. Natl Cancer Inst 2008, 100:14-20.
21. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
22. Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. lancet 2009, 373:1681-1692.
23. Berry D, Thor A, Jewell S, et al. Benefits of adding paclitaxel to adjuvant doxorubicin/cyclophosphamide depending on HER2 & ER status: analysis of tumor tissue microarrays and immunohistochemistry in CALGB 9344 (Intergroup 0148). Cancer Res 2009, 69:24s. (abstract 606).
24. Di Leo A, Francis R, Crown J, et al. Overall survival benefit for sequential doxorubicin-docetaxel compared to concomitant doxorubicin and docetaxel in node-positive breast cancer. 8-yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial. Cancer Res 2010, 69:24s. (abstract 601).
25. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
26. Treszezamsky AD, Kachnic LA, Feng Z, et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007, 67:7078-7081.
27. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-6228.
28. Tassone R, Tagliaferri R, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCAl-defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88:1285-1291.
29. Petit T, Wilt M, Rodier J, et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?. Clin Oncol 2007, 25:18s. (abstract 580).
30. Delaloge S, Pautier R Kloos I, et al. BRCAl-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Paper presented at 27th Congress of the European Society for Medical Oncology; October 18-22, 2002; Nice, France (abstract 120).
31. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med Genet 2002, 39:608-610.
32. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M Her-2/neu in systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat 2008, 109:209-229.
33. Di Leo A, Desmedt C, Bartlett JM, et al. Final results of a meta-analysis testing HER2 and topoisomerase Ha genes as predictors of incremental benefit from anthracyclines in breast cancer. J Clin Oncol 2010, 28:15s. (abstract 519).
34. Cheang M, Chia SK, Tu D, et al. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEFJ. Clin Oncol 2009, 27:15s. (abstract 519).
35. Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci 2007;17, 104:12117-12122.
36. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007, 117:1370-1380.
37. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCAl-positive breast cancers. Breast Cancer Res Treat 2009, 115:359-363.
38. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCAl-positive breast cancer patients. J Clin Oncol 2009, 27:15s. (abstract 502).
39. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCAl-positive breast cancers after neoadjuvant chemotherapy.;. Clin Oncol 2010, 28:375-379.
40. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
41. Bhattacharyya GS, Basu S, Agarwal V, et al. Single institution phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple negative. EurJ Cancer 2009, 7. (abstract 18).
42. Leone JR, Guardiola V, Venkatraman A, et al. Neoadjuvant platinum-based chemotherapy for triple-negative locally advanced breast cancer: Retrospective analysis of 125 patients. J Clin Oncol 2009, 27:15s. (abstract 625).
43. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008, 62:667-672.
44. Sikov WM, Fenton MA, Strenger R, Dizon DS, Legare RD, Graves TA Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel + weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95. Breast Cancer Res Treat 2007, 106:Is. (abstract 5063).
45. Frasci G, Cornelia R, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009, 20:1185-1192.
46. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008, 19:1847-1852.
47. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N EnglJ Med 2011, 364:205-214.
48. O'Shaughnessy J, Weckstein D, Vukelja S, et al. Preliminary results of a randomized phase II study of weekly ironotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106:ls. (abstract 308).
49. Chia JW, Ang R, See H, et al. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy. J Clin Oncol 2007, 25:18s. (abstract 1086).
50. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. IntJ Cancer 2009, 124:1457-1462.
51. Carey L, Rugo H, Marcom R, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metasatic triple-negative (basal-like) breast cancer. Clin Oncol 2008, 26(suppl;abstract 1009).
52. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.;. Clin Oncol 2008, 26:44-53.
53. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
54. Bonnefoi HR, Bogaerts J, Piccart M, et al. Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. Clin Oncol 2010, 28:18s. (abstract LBA503).
55. Jacquemier J, Penault-Llorca F, Mnif H, et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA).;. Clin Oncol 2006, 24:18s. (abstract 509).
56. Martin M, Segui MA, Anton A, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N EnglJ Med 2010, 363:2200-2210.
57. Roche H, Allouache D, Romieu G, et al. Five-year analysis of the FNCLCC-PACS04 Trial: FEC100 vs. ED75 for the adjuvant treatment of node positive breast cancer. Cancer Res 2010, 69:24s. (abstract 60).
58. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
59. Ellis GK, Green SJ, Russell CA, Royce ME, Perez EA, Livingston RB SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer.;. Clin Oncol 2006, 24:18s. (abstract LBA537).
60. Falo C, Moreno A, Varela M, et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy.;. Cancer Res Clin Oncol 2007, 133:423-429.
61. Colleoni M, Cole BF, Viale G, et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.;. Clin Oncol 2010, 28:2966-2973.
62. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
63. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR Ki67, HER2 Immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. Cancer Res 2009, 69:24s. (abstract 74).
64. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase Ha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 2005, 23:7483-7490.
65. O'Malley F, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009, 101:644-650.
66. Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010, 11:266-274.
67. Desmedt C, Azambuja E, Larsimont D, et al. Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial J C/in. Oncol 2009, 27:15s. (abstract 523).
68. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111:27-44.
69. Mo YY, Beck WT Heterogeneus expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res 1997, 9:193-204.
70. Camp RL, Chung GG, Rimm DL Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327.
71. Collins AR, AOscoz A, Brunborg G, et al. The comet assay: topical issues. Mutagenesis 2008, 23:143-151.
72. Langie SA, Knaapen AM, Brauers KJ, van Berlo D, van Shooten FJ, Godshalk RW Development and validation of a modified comet assay to phenotipically assess nucleotide excision repair. Mutagenesis 2006, 21:153-158.
73. Galardi F, Licitra S, Truglia M, et al. Evaluation of DNA damages by alkaline comet assay in early breast cancer patients. Ann Oncol 2009, 20:viii47-viii56.
74. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010, 16:6159-6168.
75. Asakawa H, Koizumi H, Koike A, et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010, 12:R17.
76. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010, 123:189-196.